Celyad Oncology S.A.
Euronext BrusselsTotal Valuation
Celyad Oncology S.A. carries a market capitalization of 10.21M, placing it among publicly traded companies globally. Its enterprise value stands at 26.49M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 10.21M |
| Enterprise Value | 26.49M |
Share Statistics
Celyad Oncology S.A. currently has 22.59M shares outstanding.
| Shares Outstanding | 22.59M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.16 |
| P/TBV Ratio | -6.52 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
| EV / Sales | N/A |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 110.80 |
Financial Position
Celyad Oncology S.A. maintains a current ratio of 1.71, meaning it holds 1.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 7.06, indicating elevated leverage, while an interest coverage ratio of -122.57 demonstrates limited ability to service its debt obligations.
| Current Ratio | 1.71 |
| Quick Ratio | 1.59 |
| Debt / Equity | 7.06 |
| Debt / EBITDA | -0.07 |
| Interest Coverage | -122.57 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -40.87 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | 10,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Celyad Oncology S.A.'s stock has declined approximately -35.41076% over the past 52 weeks. The 50-day moving average sits at 0.28, while the 200-day moving average is 0.26.
| Beta (5Y) | N/A |
| 52-Week Price Change | -35.41076% |
| 50-Day Moving Average | 0.28 |
| 200-Day Moving Average | 0.26 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -29.29M, while operating income came in at -29.29M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -29.29M |
| Pretax Income | -25.70M |
| Net Income | -25.71M |
| EBITDA | -29.29M |
| EBIT | -29.29M |
| Earnings Per Share (EPS) | -1.15 |
Balance Sheet
Celyad Oncology S.A. holds 14.39M in cash and equivalents against 2.16M in total debt, resulting in a net debt position of -14.38M. Total book value stands at -244.47M, with working capital of 8.02M providing operational flexibility.
| Cash & Cash Equivalents | 14.39M |
| Total Debt | 2.16M |
| Net Debt | -14.38M |
| Equity (Book Value) | -244.47M |
| Book Value Per Share | -10.98 |
| Working Capital | 8.02M |
Scores
Celyad Oncology S.A. posts an Altman Z-Score of -19.60, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -19.60 |